EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project

Marian Schini, Tatiane Vilaca iD, Eric Vittinghoff, Li-Yung Lui, Susan K Ewing, Austin R Thompson, Douglas C Bauer, Mary L Bouxsein, Dennis M Black, Richard Eastell iD

Journal of Bone and Mineral Research · 2024

DOI: 10.1093/jbmr/zjae040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Mineral Research, 2024. Verfasst von Marian Schini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2TN, United Kingdom. Hauptthemen laut MEDLINE: Bone Density. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS, American Society for Bone Mineral Research, FDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a common belief that antiosteoporosis medications are less effective in older adults. This study used data from randomized controlled trials (RCTs) to determine whether the anti-fracture efficacy of treatments and their effects on BMD differ in people ≥70 compared to those <70 yr. We used individual patient data from 23 RCTs of osteoporosis medications collected as part of the FNIH-ASBMR SABRE project. We assessed the following fractures: radiographic vertebral, non-vertebral, hip, all clinical, and all fractures. We used Cox proportional hazard regression to estimate treatment effect for clinical fracture outcomes, logistic regression for the radiographic vertebral fracture outcome, and linear regression to estimate treatment effect on 24-mo change in hip and spine BMD in each age subgroup. The analysis included 123 164 (99% female) participants; 43% being ≥70 yr. Treatment with anti-osteoporosis drugs significantly and similarly reduced fractures in both subgroups (eg, odds ratio [OR] = 0.47 and 0.51 for vertebral fractures in those below and above 70 yr, interaction P = .19; hazard ratio [HR] for all fractures: 0.72 vs 0.70, interaction P = .20). Results were similar when limited to bisphosphonate trials with the exception of hip fracture risk reduction which was somewhat greater in those <70 (HR = 0.44) vs ≥70 (HR = 0.79) yr (interaction P = .02). Allocation to anti-osteoporotic drugs resulted in significantly greater increases in hip and spine BMD at 24 mo in those ≥70 compared to those <70 yr. In summary, anti-osteoporotic medications similarly reduced the risk of fractures regardless of age, and the few small differences in fracture risk reduction by age were of uncertain clinical significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityHumansFemaleAgedMaleMiddle AgedRandomized Controlled Trials as TopicAge FactorsFractures, BoneTreatment OutcomeOsteoporosisAged, 80 and overBone Density Conservation Agents

Stichwörter der Autor:innen

BMDSABREagebisphosphonatesosteoporosistreatment

Substanzen

Bone Density Conservation Agents

Autor:innen und Institutionen

  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2TN, United Kingdom.
  • Department of Epidemiology & Biostatistics, University of California, San Francisco, CA 94158, United States.
  • California Pacific Medical Center Research Institute, San Francisco, CA 94158, United States.
  • Department of Medicine, University of California, San Francisco, CA 94158, United States.
  • Department of Orthopedic Surgery, Harvard Medical School, Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, MA 02215330, United States.

ORCID-Profile: Tatiane Vilaca, Richard Eastell

Förderung

  • FDA HHS
  • American Society for Bone Mineral Research
  • FDA

Zitieren

APA

Schini, M., Vilaca, T., Vittinghoff, E., Lui, L. Y., Ewing, S. K., Thompson, A. R., Bauer, D. C., Bouxsein, M. L., Black, D. M., & Eastell, R. (2024). Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project. Journal of Bone and Mineral Research. https://doi.org/10.1093/jbmr/zjae040

Vancouver

Schini M, Vilaca T, Vittinghoff E, Lui LY, Ewing SK, Thompson AR, et al. Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project. Journal of Bone and Mineral Research. 2024. doi:10.1093/jbmr/zjae040

BibTeX
@article{Schini2024,
  author = {Schini, Marian and Vilaca, Tatiane and Vittinghoff, Eric and Lui, Li-Yung and Ewing, Susan K and Thompson, Austin R and Bauer, Douglas C and Bouxsein, Mary L and Black, Dennis M and Eastell, Richard},
  title = {Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project},
  journal = {Journal of Bone and Mineral Research},
  year = {2024},
  doi = {10.1093/jbmr/zjae040}
}
Kostenlos starten →